Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Seven of every 10 general practice encounters are for chronic conditions. Three common chronic conditions managed by GPs are depression, diabetes and asthma. Two of these are National Health Priority Areas (NHPAs), while depression is the focus of the mental health NHPA. General practice care for people with depression is being strengthened by the "Better outcomes in mental health care initiative", which includes a 3 Step Mental Health Process - assessment, mental health plan, and review. GPs have the opportunity to screen patients for diabetes and manage their condition. For those with risk factors who screen negative, GPs are well placed to encourage lifestyle interventions. Two of the four components of the National Integrated Diabetes Program focus on general practice. The Asthma 3+ Visit Plan, which incorporates diagnosis and assessment of asthma, development of a written asthma plan, and review of asthma management, has been shown to improve GPs' management of asthma. These initiatives to improve general practice interventions for chronic illness, although welcomed, put further pressure on already overstretched GPs coping with multiple changes in the primary-care sector.
 ...
PMID:Meeting the challenge of chronic illness in general practice. 1292 71

The implementation of guidelines for medical therapy of heart failure may be problematic for the following reasons: 1. Elderly patients and women were underrepresented in large clinical trials which may limit their therapeutic impact in these patients. 2. Therapeutic decisions are influenced by co-morbidities like renal failure, obstructive airway disease (COLD, Asthma), stroke, and diabetes mellitus. We therefore discuss the differential therapy of heart failure in view of particular patient subgroups.
 ...
PMID:[Differential therapy of heart failure. Which drug for which patient?]. 1552 78

Obesity and smoking are the two modifiable risk factors that contribute the most for many chronic diseases. Obesity has nearly doubled in Oklahoma and in the US since 1990 while Oklahoma adult smoking rates have remained above 25%. The purpose of this study was to utilize the Behavioral Risk Factor Surveillance System (BRFSS) to describe the associations between overweight, obesity, and cigarette smoking with selected chronic diseases among Oklahoma adults. The BRFSS is an ongoing, state-based, random-digit dialing telephone survey of the non-institutionalized adult population ages 18 years and older designed to collect various kinds of health-related information. Descriptive statistics were obtained for high blood pressure, high cholesterol, diabetes, asthma, and arthritis by BMI status (i.e. not overweight, overweight, obese) and smoking status (i.e., current, former, never). Logistic regression was performed to test for associations between BMI status or smoking status and these diseases. Self-reported diabetes, arthritis, and lifetime high blood pressure and high cholesterol rates were higher among those who were overweight and highest among those who were obese, while asthma rates were higher among obese adults than those who were not obese. Asthma rates were higher for those who currently smoke than former smokers and never smokers. Former smokers had significantly higher rates of high blood pressure, high cholesterol, diabetes, and arthritis compared to never smokers or current smokers.
 ...
PMID:Association of obesity and smoking with chronic diseases among Oklahoma adults. 1555 41

Asthma is a chronic disease that is highly prevalent around the world with increasing societal and economic burden. National Asthma Educational and Preventive Program (NAEPP) and Global Initiative for Asthma (GINA) are evidence-based documents designed to help clinicians make appropriate decisions for their patients and to reduce undesirable variation in the care of asthmatic patients. It is a generally accepted fact that asthma specialists achieved better and improved asthma outcomes for their patients when compared with primary care physicians (PCPs). These outcome differences are somewhat related to PCPs' poor adherence to published NAEPP guidelines. Multi-Colored Simplified Asthma Guideline Reminder (MSAGR) is the first user-friendly single-sheet convenient asthma tool designed for clinicians after barriers to the poor adherence to asthma guidelines in primary care settings were identified. Voluntary acceptance and utilization of MSAGR resulted in fewer emergency room visits and hospitalizations for their patients. General acceptance of MSAGR (more than 1 million copies requested by clinicians globally), and overwhelming positive comments by asthma care providers, strongly advocate a need for real-time, pragmatic clinical tools not only in asthma, but also in other chronic diseases such as chronic obstructive pulmonary disease, diabetes mellitus, hypertension, and depression, etc. In this brief review, we discuss how clinicians, patients, and payers are utilizing these simplified asthma tools to improve asthma care in their community.
 ...
PMID:Multi-colored simplified asthma guideline reminder: why pragmatic asthma tools are needed in real-world practice. 1557 97

Asthma is a common disease that affects between 5.5% and 7.0% of the population. It is an example of a disease where good guidelines and an accepted model of treatment exist, but have not been fully implemented. In the latter part of 2000, Blue Cross Blue Shield of Minnesota (BCBSM) had existing and successful disease management (DM) programs for diabetes and heart disease and was looking to expand the concept to other diseases. Asthma was one of the conditions under consideration. This study, done in conjunction with PharMetrics, Inc. of Watertown, MA was done to establish the opportunity present to help Blue Cross members with the disease, and to help decide whether developing such a program made sense for the health plan. In addition, if the answer to the second question were yes, the study would lay the groundwork for that program. Using 2 years of BCBSM claims data, the study identified, stratified, and analyzed the cohort of BCBSM members with a diagnosis of asthma according to severity of illness, individual drug or drug combination treatment, emergency room usage, hospitalization, and total episode costs for asthma. Health plan results were bench-marked against the experience of others across the country represented in the (then) 20+ million managed care lives in PharMetrics' Integrated Outcomes Database. The results showed that in some of the recommended guidelines for asthma care BCBSM members led the nation in compliance, but that there was ample opportunity for improvement thus justifying moving forward in developing a disease management program. The results also seemed to validate many of the recommendations for asthma care expressed in the Expert Panel Report 2 on the diagnosis and treatment of asthma from the National Heart Lung and Blood Institute of the National Institutes of Health.
 ...
PMID:Building the case for asthma as a disease management program. 1566 80

Our objective was to determine the impact of gender and age on asthma hospitalization rates among children. We used a population-based retrospective birth cohort study to determine yearly age- and gender-specific asthma hospitalization rates between ages 2-18 years in a cohort of all children born in Washington State between 1980-1985. In addition, we assessed factors associated with the hospitalization of a given child for asthma both before and during adolescence, and factors associated with an initial asthma hospitalization during adolescence. Outcome measures included age- and gender-specific rates of hospitalization for asthma, diabetes, seizures/epilepsy, and nonasthma respiratory diagnoses. Asthma hospitalization rates for boys were significantly higher than for girls between ages 2-12 years, the gender gap in asthma hospitalizations reversed between ages 13-14 years, and rates for girls were significantly higher than boys between 16-18 years of age. The male peak asthma hospitalization rate per 100,000 cohort members occurred at age 4 years (12.7; 95% confidence interval (CI), 11.1-14.3), and the male trough rate occurred at age 18 years (4.1; 95% CI, 2.8-5.4), whereas the female peak asthma hospitalization rate occurred at age 17 years (9.4; 95% CI, 7.8-11) and the female trough rate at age 2 years (5.2; 95% CI, 4.2-6.2). Age-specific hospitalization rates for diabetes mellitus and epilepsy were similar for boys and girls throughout childhood. Female gender was strongly associated with asthma hospitalization occurring in an individual child both prior to and during adolescence (rate ratio (RR), 2.0; 95% CI, 1.4-2.9), and was modestly associated with initial hospitalization in adolescence (RR, 1.15; 95% CI, 1.0-1.3). In conclusion, asthma hospitalization rates for boys and girls exhibit strikingly different patterns during adolescence. Potential explanations for these gender differences include hormonal changes during puberty, or gender-specific differences in environmental exposures such as diet, obesity, allergen exposure, or cigarette smoking.
 ...
PMID:Impact of adolescence and gender on asthma hospitalization: a population-based birth cohort study. 1569 May 59

Asthma is a very common chronic disease that occurs in all age groups and is the focus of various clinical and public health interventions. Both morbidity and mortality from asthma are significant. The number of disability-adjusted life years (DALYs) lost due to asthma worldwide is similar to that for diabetes, liver cirrhosis and schizophrenia. Asthma management plans have, however, reduced mortality and severity in countries where they have been applied. Several barriers reduce the availability, affordability, dissemination and efficacy of optimal asthma management plans in both developed and developing countries. The workplace environment contributes significantly to the general burden of asthma. Patients with occupational asthma have higher rates of hospitalization and mortality than healthy workers. The surveillance of asthma as part of a global WHO programme is essential. The economic cost of asthma is considerable both in terms of direct medical costs (such as hospital admissions and the cost of pharmaceuticals) and indirect medical costs (such as time lost from work and premature death). Direct costs are significant in most countries. In order to reduce costs and improve quality of care, employers and health plans are exploring more precisely targeted ways of controlling rapidly rising health costs. Poor control of asthma symptoms is a major issue that can result in adverse clinical and economic outcomes. A model of asthma costs is needed to aid attempts to reduce them while permitting optimal management of the disease. This paper presents a discussion of the burden of asthma and its socioeconomic implications and proposes a model to predict the costs incurred by the disease.
 ...
PMID:The public health implications of asthma. 1617 30

The objective of this research was to compare the accuracy of two types of neural networks in identifying individuals at risk for high medical costs for three chronic conditions. Two neural network models-a population model and three disease-specific models-were compared regarding effectiveness predicting high costs. Subjects included 33,908 health plan members with diabetes, 19,264 with asthma, and 2,605 with cardiac conditions. For model development/ testing, only members with 24 months of continuous enrollment were included. Models were developed to predict probability of high costs in 2000 (top 15% of distribution) based on 1999 claims factors. After validation, models were applied to 2000 claims factors to predict probability of high 2001 costs. Each member received two scores-population model score applied to cohort and disease model score. Receiver Operating Characteristic (ROC) curves compared sensitivity, specificity, and total performance of population model and three disease models. Diabetes-specific model accuracy, C = 0.786 (95%CI = 0.779-0.794), was greater than that of population model applied to diabetic cohort, C = 0.767 (0.759-0.775). Asthma-specific model accuracy, C = 0.835 (0.825-0.844), was no different from that of population model applied to asthma cohort, C = 0.844 (0.835-0.853). Cardiac-specific model accuracy, C = 0.651 (0.620-0.683), was lower than that of population model applied to cardiac cohort, C = 0.726 (0.697-0.756). The population model predictive power, compared to the disease model predictive power, varied by disease; in general, the larger the cohort, the greater the advantage in predictive power of the disease model compared to the population model. Given these findings, disease management program staff should test multiple approaches before implementing predictive models.
 ...
PMID:Comparative effectiveness of total population versus disease-specific neural network models in predicting medical costs. 1621 13

Although we aim to normalize the lives of children with asthma by controlling their day and night symptoms and preventing exacerbations and morbidity, optimal childhood asthma management may result when the assessment and monitoring of asthma includes measured biomarkers--meaning objective, biological measures of lung dysfunction and inflammation. Precedence for such an approach to optimizing disease control and outcomes can be appreciated in comparing asthma with insulin-dependent diabetes mellitus (IDDM) management in children. Optimal management of these chronic conditions shares the fundamental goals to eliminate day and night symptoms and prevent exacerbations and morbidity. However, IDDM management focuses primarily on peripheral blood biomarkers of tight control (i.e., daily serum glucose levels) and predictors of long-term morbidity (i.e., hemoglobin A1C, or hemoglobin "remodeling" due to chronically poor control of glucose) for optimal assessment and monitoring and to best achieve these clinical objectives (Alemzadeh R, et al. Diabetes mellitus in children. In Nelson Textbook of Pediatrics, 17th ed. Behrman RE, Kliegman RM, and Jenson HB (Eds). Philadelphia: W.B. Saunders Co., 1947-1972, 2004). The improved outcomes in IDDM have resulted primarily from the progress to a biomarker-based assessment to achieve tight, optimal control and not, presently, as a dramatic change in therapy. The progress in IDDM management provides a compelling paradigm to consider for improving childhood asthma management. Indeed, the time is good to not only consider some newly available biomarkers, but also to reconsider some biomarkers of lung dysfunction, inflammation, and atopy that could be broadly used today. This article reconsiders the use of current and emerging measures of lung dysfunction, inflammation, and atopy in assessing tight control and long-term risk. Concluding emphasis will be placed on what can be implemented today.
Allergy Asthma Proc
PMID:Biomarkers and childhood asthma: improving control today and tomorrow. 1627 Jul 16

Although antimicrobial resistance to Streptococcus pneumoniae has been increased dramatically worldwide, there is limited information of pattern of susceptibility for this pathogen in Puerto Rico. Hospital-based surveillance for invasive pneumococcal infections was begun among 38 hospitals island-wide in Puerto Rico from January to December, 2001. One hundred ninety-two cases of invasive pneumococcal disease were identified. Of the 177 isolates available for susceptibility testing, 50.3% were susceptible to penicillin and 49.7% were nonsusceptible (intermediate (I) and resistance (R)) (19.2% I, 30.5% R). Resistance was documented for expanded spectrum cephalosporins and macrolides. All isolates were susceptible to vancomycin. Diabetes, cardiovascular disease, smoking and bronchial asthma were the most common risk factors associated with invasive pneumococcal disease of the adult population. Bronchial asthma was the most common disease in the pediatric population with a fatality rate of 21%. There was no increased mortality detected among patients infected with penicillin resistant strains. Most of the isolates serotypes are represented in the 23-valent polysaccharide vaccine (78%) and 7-valent conjugate vaccine (62%). Penicillin-resistant isolates (47%) were 14, 19F, 6B, 6A, 9V, 23F, 19A and 35B serotype. Our data indicated a high prevalence for drug-resistant strains of S. pneumoniae in Puerto Rico. Continue surveillance for this common but serious pathogen is needed. Asthma is an important risk factor for pneumococcal disease. The pneumococcal vaccine should be recommended for all age groups with this risk factor.
 ...
PMID:A multicenter hospital surveillance of invasive Streptococcus pneumoniae, Puerto Rico, 2001. 1632 81


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>